Prostate cancer screening, involving markers such as prostate-specific antigen, has enabled the detection and diagnosis of prostate cancer much earlier in life and at an earlier stage of disease. This earlier diagnosis, with the potential for earlier and longer endocrine exposure, has implications on treatment options for early prostate cancer. Treatment options that need to be considered are immediate versus deferred treatment, adjuvant therapy, intermittent treatment and step-up treatment. Preliminary reports indicate advantages for immediate compared with deferred therapy in terms of time to progression and overall survival. There are studies in progress for the other treatment options that should resolve some of the uncertainties about the management of early prostate cancer. The need to balance long-term side effects against potential survival advantage is of particular importance in patients who may be receiving endocrine therapy for longer periods. As antiandrogens are associated with quality of life benefits when compared with castration, the non-steroidal antiandrogen bicalutamide, which is currently being investigated as monotherapy1 and as adjuvant therapy, may prove to be a useful treatment option for patients with early prostate cancer.

Keywords:
Prostate cancer, Hormonal therapy, Quality of life
1.
Visser O, Horenblas S: Incidence and treatment of prostatic carcinoma in the region of the Comprehensive Cancer Center Amsterdam, 1989–1994. Ned Tijdschr Geneeskd 1996;140:2627–2631.
2.
Rietbergen JB, Hoedemaeker RF, Kruger AE, Kirkels WJ, Schröder FH: The changing pattern of prostate cancer at the time of diagnosis: Characteristics of screen detected prostate cancer in a population based screening study. J Urol 1999;161:1192–1198.
3.
Van den Ouden D, Hop WCJ, Kranse R, Schröder FH: Tumour control according to pathological variables in patients treated by radical prostatectomy for clinically localized carcinoma of the prostate. Br J Urol 1997;79:203–211.
4.
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591–1597.
5.
Anderson JB: Early versus deferred hormone therapy. Eur Urol 1999;36(suppl 2):9–13.
6.
The Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council trial. Br J Urol 1997;79:235– 246.
7.
Van den Ouden D, Tribukait B, Blom JHM, Fossa SD, Kurth KH, Ten Kate FJW, Heiden T, Wang N, Schröder FH, and the European Organization for Research and Treatment of Cancer Genitourinary Group: Deoxyribonucleic acid ploidy of core biopies and metastatic lymph nodes of prostate cancer patients: Impact on time to progression. J Urol 1993;150:400–406.
8.
Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K: Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report. Urology 1995;45:839–845.
9.
Schröder FH: Endocrine treatment of prostate cancer – Recent developments and the future. Part 1: Maximal androgen blockade, early vs delayed endocrine treatment and side-effects. BJU Int 1999;83:161–170.
10.
Daniell HW: Osteoporosis after orchiectomy for prostate cancer. J Urol 1997;157:439–444.
11.
Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G: Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997;79:933–941.
12.
Braunstein GD: Gynaecomastia. N Engl J Med 1993;328:490–495.
13.
Decensi AU, Boccardo F, Guarneri D, Positano N, Paoletti MC, Costantini M, Martorana G, Giuliani L for the Italian Prostatic Cancer Project: Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. J Urol 1991;146:377–381.
14.
Fass D, Steinfeld A, Brown J, Tessler A: Radiotherapeutic prophylaxis of estrogen-induced gynecomastia: A study of late sequela. Int J Radiat Oncol Biol Phys 1986;12:407–408.
15.
Warner CL, Griffin JE, Wilson JD, Jacobs LD, Murray KR, Fischbeck KH, Dickoff D, Griggs RCl: X-linked spinomuscular atrophy: A kindred with associated abnormal androgen receptor binding. Neurology 1992;42:2181– 2184.
16.
Wirth MP, Iversen P, See W, McLeod D: Bicalutamide (CasodexTM) early prostate cancer programme – Final demographic data from over 8000 randomised patients. Eur Urol 1999;35(suppl 2):13 (Abstr 52).
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.